1. Home
  2. CYCU vs LEXX Comparison

CYCU vs LEXX Comparison

Compare CYCU & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$2.85

Market Cap

17.8M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.62

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
LEXX
Founded
2017
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYCU
LEXX
Price
$2.85
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
157.3K
1.5M
Earning Date
11-14-2025
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,667,874.00
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$2.11
$0.46
52 Week High
$2,008.94
$2.43

Technical Indicators

Market Signals
Indicator
CYCU
LEXX
Relative Strength Index (RSI) 45.38 38.26
Support Level $2.56 $0.46
Resistance Level $3.00 $0.64
Average True Range (ATR) 0.30 0.12
MACD -0.08 -0.02
Stochastic Oscillator 27.78 17.19

Price Performance

Historical Comparison
CYCU
LEXX

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: